This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HOLX Launches BustTheMyth Campaign for Breast Health Awareness
by Zacks Equity Research
Hologic enters Breast Cancer Awareness Month with the launch of the BustTheMyth campaign. This campaign is aimed at busting myths regarding breast health.
Why Endo (ENDP) Stock Wilted After its Surge on Tuesday?
by Zacks Equity Research
Endo International (ENDO) tanks 26%, cooling off after its massive stock price surge on Tuesday, post the Supreme Court's decision to overturn Roe v. Wade.
Is the Options Market Predicting a Spike in Evofem Biosciences (EVFM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Evofem Biosciences (EVFM) stock based on the movements in the options market lately.
Do Options Traders Know Something About Evofem Biosciences (EVFM) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Evofem Biosciences (EVFM) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Evofem Biosciences (EVFM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Evofem Biosciences (EVFM) stock based on the movements in the options market lately.
Evofem Biosciences (EVFM) Looks Good: Stock Adds 10.1% in Session
by Zacks Equity Research
Evofem Biosciences (EVFM) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Company News for May 27, 2020
by Zacks Equity Research
Companies In The News Are: EVFM, BNFT, SRNE, CLRB
Are Options Traders Betting on a Big Move in Evofem Biosciences (EVFM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Evofem Biosciences (EVFM) stock based on the movements in the options market lately.
PDL BioPharma (PDLI) Misses on Q4 Earnings, To Dissolve by Year-End
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings lag estimates in the fourth quarter. The company announces plan to complete liquidation by the end of 2020.
PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales
by Zacks Equity Research
PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well. However, revenues fall year over year.
PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.
PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts
by Zacks Equity Research
PDL BioPharma (PDLI) aims to acquire and manage high-yielding assets and maximize shareholder value. Blindly falling back on partners for royalties is a persistent concern.
PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues
The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY
by Zacks Equity Research
A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.
Evofem Shares Up as Birth Control Gel Succeeds in Phase III
by Zacks Equity Research
Evofem (EVFM) stock surges on positive results from a late-stage study on experimental birth control vaginal gel.
3 Small Biotech Stocks That Almost Doubled in Past Month
by Zacks Equity Research
We take a look at three biotech stocks, prices of which have almost doubled in the past month.